Agenus | AGEN - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Agenus USD 3.46M 6.08M 2025-09
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Celldex Therapeutics USD 28.87M 7.17M 2025-12
CSL USD 2.16B 633M 2025-06
Eli Lilly USD 7.27B 2.52B 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Glaxosmithkline GBP 3.3B 303M 2025-09
Incyte USD 3.58B 650.78M 2025-12
Intrexon USD 9.34M 1.77M 2024-06
J&J USD 19.71B 1.48B 2025-12
Jiangsu Hengrui CNY 40.36B 4.24B 2025-09
Karyopharm Therapeutics USD 37.67M 1.05M 2025-09
MacroGenics USD 57.22M 22.91M 2025-12
Merck EUR 2.25B 1.08B 2025-09
Merck USD 18.17B 10.16B 2025-09
Northwest Biotherapeutics USD 4.56M 244K 2025-09
Novartis USD 9.56B 2.9B 2025-09
Novavax USD 240.63M 27.39M 2025-12
Pfizer USD 1.34B 295M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Veracyte USD 362.58M 47M 2025-12